Insights & Publications

Pharmaceuticals & Medical Products

article

Healthcare’s digital future

July 2014—Insights from our international survey can help healthcare organizations plan their next moves in the journey toward full digitization.more

Editor's choice

Donaldson_1536x1536_Thumbnail
interview

Designing for social impact: The D-Rev story

June 2014—Many companies target the world’s emerging middle-class consumers. Fewer mirror nonprofit D-Rev, which aims to improve the health and lives of people living on less than $4 a day.more

  • includes:
    •  
Pharma-launches_1536x1536_Thumbnail
article

The secret of successful drug launches

March 2014—About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly.more

Pharma-mergers_1536x1536_Thumbnail
article

Why pharma megamergers work

February 2014—Unlike deals in many industries, big mergers and acquisitions among pharmaceutical companies generally have resulted in positive returns to shareholders.more

FDAapprovals_1536x1152_Thumbnail
article

What’s driving the surge in new-drug approvals?

November 2013—In 2012, new-drug approvals by the US Food and Drug Administration hit a ten-year high. Can the pharmaceutical industry make this trend last?more

HealthCareSupplyChain_1536x1152_Thumbnail
article

Strengthening health care’s supply chain: A five-step plan

September 2013—Dramatically changing the sector’s inefficient supply chain may eliminate the dangers posed by counterfeiting and medication errors.more

  • includes:
    •  
hobi13_frth_Thumbnail
article

How big data can revolutionize pharmaceutical R&D

April 2013—Pharmaceutical R&D suffers from declining success rates and a stagnant pipeline. Big data and the analytics that go with it could be a key element of the cure.more

  • includes:
    •  
heca12_frth_Thumbnail
article

Health care in China: Entering ‘uncharted waters’

November 2012—Multinationals are flocking to take advantage of the opportunities, but long-term success is by no means assured.more

reva12_1536x1152_Thumbnail
article

Restoring value to biopharmaceutical R&D

August 2012—After years of seeing value destroyed by R&D excesses, biopharmaceutical companies can gain healthier returns—but only if they recognize several new imperatives.more

About this content

The material on this page draws on the research and experience of McKinsey consultants and other sources. To learn more about our expertise, please visit the Pharmaceuticals & Medical Products Practice.